Gelonghui, November 13 | According to the China Galaxy Securities Research Report, Dian Diagnostics (300244.SZ) is the leading third-party medical testing service provider in China. With the development of integrated “product+service”, regular business is expected to maintain rapid growth over a long period of time as the national layout is improved, operational efficiency continues to increase, and the share of special examinations continues to increase. From January to September 2023, the routine diagnosis business reached 4,080 billion yuan (+17.07%). As the company's medical diagnosis services return to regular business, routine business is expected to grow rapidly in the future. The current stock price corresponding to 2023-2025 PE is 20/13/10 times, maintaining the “recommended” rating.